← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for inhalation
insulin (human)
A10AF01
Forms & Strengths
- Injection: 100 units/mL (U-100) in vials, cartridges, and pre-filled pens
Adult Dosing
- Type 1 Diabetes: 0.4 to 1.0 units/kg/day divided subcutaneously in multiple daily doses basal-bolus
- Type 2 Diabetes: Initial basal dose 0.1 to 0.2 units/kg/day or 10 units daily, titrated based on fasting blood glucose
Pediatric Dosing
- Type 1 Diabetes: 0.2 to 1.0 units/kg/day subcutaneously divided into multiple daily doses adjusted for growth and puberty
Indications
- Glycemic control in adult and pediatric patients with type 1 or type 2 diabetes mellitus
Mechanism of Action
- Binds to insulin receptors on muscle and fat cells, stimulating glucose uptake and inhibiting hepatic glucose production, lipolysis, and proteolysis
Contraindications
- Hypoglycemic episodes
- Hypersensitivity to human insulin or any excipient
Adverse Reactions
- Hypoglycemia
- Weight gain
- Lipodystrophy or lipoatrophy at injection sites
- Hypersensitivity reactions
- Injection site reactions
- Hypokalemia
Drug Interactions
- Antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs, and sulfonamides may increase hypoglycemia risk
- Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetics, and thyroid hormones may decrease blood glucose-lowering effect
- Beta-blockers, clonidine, guanethidine, and reserpine may mask signs of hypoglycemia
Curated Content: Needs Vetting Before Put to Clinical Use